(4'-chloro-biphenyl-4-yloxy)-acetic acid | 689300-77-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4'-chloro-biphenyl-4-yloxy)-acetic acid
• 英文别名: 2-[4-(4-chlorophenyl)phenoxy]acetic acid
• CAS: 689300-77-4
• 化学式: C₁₄H₁₁ClO₃
• 分子量: 262.693
• InChiKey: IYQQYLICORZSQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4'-chloro-biphenyl-4-yloxy)-acetic acid 在 盐酸羟胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 potassium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 5-(((4′-chloro-[1,1′-biphenyl]-4-yl)oxy)methyl)-N-hydroxy-1,2,4-oxadiazole-3-carboxamide
  参考文献：
  名称：

  Discovery of Novel N-Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis

  摘要：

  DOI：

  10.1021/acs.jmedchem.2c01643
• 作为产物：
  描述：

  (4'-chloro-biphenyl-4-yloxy)-acetic acid tert-butyl ester 在 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 16.0h， 以100%的产率得到(4'-chloro-biphenyl-4-yloxy)-acetic acid
  参考文献：
  名称：

  [DE] NEUE AMID-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL
  [EN] NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS
  [FR] NOUVEAUX COMPOSES DE TYPE AMIDE EXERÇANT UNE ACTION ANTAGONISTE SUR L'HORMONE MCH, ET MEDICAMENTS CONTENANT CES COMPOSES

  摘要：

  该发明涉及通式（I）的酰胺化合物，其中基团和残基A、B、b、W、X、Y、Z、R1、R2和R3具有权利要求1中所述的含义。此外，该发明涉及含有至少一种根据本发明的酰胺的药物。由于MCH受体拮抗活性，根据本发明的药物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。

  公开号：

  WO2004039764A1

文献信息

• Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040152742A1

  公开（公告）日：2004-08-05

  The present invention relates to amide compounds of general formula I 1 wherein the groups and residues A, B, b, W, X, Y, Z, R 1 , R 2 and R 3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的酰胺化合物，其中基团和残基A、B、b、W、X、Y、Z、R1、R2和R3具有权利要求1中给出的含义。此外，本发明涉及至少含有本发明中一种酰胺的药物组合物。鉴于MCH受体拮抗活性，本发明中的药物组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• Low plate-out polycarbonates
  申请人：GENERAL ELECTRIC COMPANY

  公开号：EP0324917A1

  公开（公告）日：1989-07-26

  Polycarbonate resins are chain-terminated with a group selected from those of the formula: wherein R₁, R₂ and R₃ are each independently selected from the group consisting of hydrogen, halogen, hydrocarbyl of from 1 to 12 carbon atoms, inclusive; and halogen-substituted hydrocarbyl of 1 to 12 carbon atoms, inclusive; R₁ is attached to a ring carbon atom at one of the 4, 5 or 6 positions; and R₂ and R₃ when taken together represent the divalent moiety of formula: - CH = CH₂ - CH₂= CH - which effectively creates an additional fused aromatic ring structure. The resins exhibit a low plate-out when processed thermally.

  聚碳酸酯树脂用选自以下式子的基团链端化： 其中 R₁、R₂ 和 R₃ 各自独立地选自氢、卤素、1 至 12 个碳原子（包括 12 个碳原子）的烃基和 1 至 12 个碳原子（包括 12 个碳原子）的卤素取代的烃基；R₁ 在 4、5 或 6 位之一连接至环状碳原子；以及 R₂ 和 R₃ 合在一起代表式中的二价分子： - ch = ch₂ - ch₂= ch - 这实际上形成了一个额外的融合芳香环结构。这种树脂在热加工时显示出较低的塑性。
• Design, synthesis and evaluation of MCH receptor 1 antagonists—Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition
  作者：Gerald J. Roth、Armin Heckel、Jörg T. Kley、Thorsten Lehmann、Stephan G. Müller、Thorsten Oost、Klaus Rudolf、Kirsten Arndt、Ralph Budzinski、Martin Lenter、Ralf R.H. Lotz、Marcus Schindler、Leo Thomas、Dirk Stenkamp

  DOI：10.1016/j.bmcl.2015.05.074

  日期：2015.8

  Despite recent success there remains a high therapeutic need for the development of drugs targeting diseases associated with the metabolic syndrome. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, a series of 3,6-disubstituted pyridazines was evaluated. During optimization several issues of the initial lead structures had to be resolved, such as selectivity over related GPCRs, inhibition of the hERG channel as well as the potential to induce phospholipidosis. Utilizing property-based design, we could demonstrate that all parameters can significantly be improved by consequently increasing the polarity of the compounds. By this strategy, we succeeded in identifying potent and orally available MCH-R1 antagonists with good selectivity over M1 and 5-HT2A and an improved safety profile with respect to hERG inhibition and phospholipidosis. (C) 2015 Elsevier Ltd. All rights reserved.
• NEUE AMID-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL
  申请人：BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

  公开号：EP1558567A1

  公开（公告）日：2005-08-03
• US4841015A
  申请人：——

  公开号：US4841015A

  公开（公告）日：1989-06-20